Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay

Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection or vaccination, but concern exists around ability to make timely assessment of immune s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pallett, Scott J.C., Rayment, Michael, Heskin, Joseph, Mazzella, Andrea, Jones, Rachael, Mughal, Nabeela, Randell, Paul, Davies, Gary W., Moore, Luke S.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371766/
https://www.ncbi.nlm.nih.gov/pubmed/36084423
http://dx.doi.org/10.1016/j.diagmicrobio.2022.115788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371766/
https://www.ncbi.nlm.nih.gov/pubmed/36084423
http://dx.doi.org/10.1016/j.diagmicrobio.2022.115788

Ejemplares similares